IDEXX Laboratories Announces First Quart...(om the three months ended March 31 2009 ...),Health

Date:4/24/2009

om the three months ended March 31, 2009 to the three months ended March 31, 2008. (2) Represents the percentage change in revenue during the three months ended March 31, 2009 compared to the three months ended March 31, 2008 attributed to incremental revenues from businesses acquired or revenues lost from businesses divested subsequent to December 31, 2007. (3) Organic growth IDEXX Laboratories, Inc. and Subsidiaries Consolidated Balance Sheet Amounts in thousands (Unaudited) March 31, December 31, 2009 2008 Assets: Current Assets: Cash and cash equivalents $86,295 $78,868 Accounts receivable, net 115,253 111,498 Inventories 123,575 115,926 Other current assets 42,660 49,598 Total current assets 367,783 355,890 Property and equipment, at cost 322,949 320,198 Less: accumulated depreciation 136,241 130,552 Property and equipment, net 186,708 189,646 Other long-term assets, net 216,013 219,901 Total assets $770,504 $765,437 Liabilities and Stockholders' Equity: Current Liabilities: Accounts payable $23,541 $28,006 Accrued expenses 91,477 104,616 Debt 166,294 151,385 Deferred revenue 10,831 11,285 Total current liabilities
'/>"/>

SOURCE IDEXX Laboratories, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. IDEXX Laboratories to Present at JPMorgan Healthcare Conference
2. IDEXX Laboratories to Release 2007 Fourth Quarter and Full-Year Financial Results
3. IDEXX Laboratories Announces Fourth Quarter Results
4. IDEXX Laboratories Announces Increase in Share Repurchase Program
5. IDEXX Laboratories to Release 2008 First Quarter Financial Results
6. IDEXX Laboratories to Present at William Blair 28th Annual Growth Stock Conference
7. IDEXX Laboratories Names William Brown Corporate Vice President
8. IDEXX Laboratories to Release 2008 Fourth Quarter and Full-Year Financial Results
9. IDEXX Laboratories Announces Fourth Quarter and Full Year Results
10. IDEXX Laboratories to Release 2009 First Quarter Financial Results
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)